European Medicines Association (EMA) statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC)
The European Medicines Association (EMA) issued a statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC) on 28 06 2024.
The EMA has recommended that the marketing authorisation for Ocaliva be revoked in the European Union following results of the COBALT trial, 747-302 . In the UK EMA recommendations do not apply, as we are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). At present, there are no changes to the recommendations on use of Obeticholic acid in PBC from the MHRA or the National Institute for Health and Care Excellence (NICE) and so current prescribing practices should NOT change.
We shall update the UK liver community if there are any changes to the recommendations on the use of Obeticholic acid.
Sheffield consultant wins international award for irritable bowel syndrome work
Dr Imran Aziz, honorary consultant gastroenterologist at Sheffield Teaching Hospitals NHS Foundation Trust and senior clinical lecturer at the University of Sheffield, was presented with the Rome Foundation Academic Fellowship in recognition of his exceptional scientific research and clinical impact in gastroenterology services.
New Impact Factors announced for BSG Journals
Gut, one of the world’s leading journals in gastroenterology, has once again cemented its position at the forefront of the specialty with a newly released Impact Factor of 25.8, as announced in the latest Journal Citation Reports (JCR) from Clarivate.
Spring 2025 BSG Elections Results
The spring 2025 BSG elections results are now in! Check out who your new elected members and representatives are.